[HTML] nih.gov

[HTML][HTML] Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

RECOVERY Collaborative Group - Lancet (London, England …, 2021 - pmc.ncbi.nlm.nih.gov
Background In this study, we aimed to evaluate the effects of tocilizumab in adult patients
admitted to hospital with COVID-19 with both hypoxia and systemic inflammation. Methods
This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19
Therapy [RECOVERY]), is assessing several possible treatments in patients hospitalised
with COVID-19 in the UK. Those trial participants with hypoxia (oxygen saturation< 92% on
air or requiring oxygen therapy) and evidence of systemic inflammation (C-reactive protein≥ …
Save Cite Cited by 1235 Related articles All 24 versions
[HTML] nih.gov

[HTML][HTML] Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

RECOVERY Collaborative Group - Lancet (London, England …, 2021 - pmc.ncbi.nlm.nih.gov
Background Many patients with COVID-19 have been treated with plasma containing anti-
SARS-CoV-2 antibodies. We aimed to evaluate the safety and efficacy of convalescent
plasma therapy in patients admitted to hospital with COVID-19. Methods This randomised,
controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy
[RECOVERY]) is assessing several possible treatments in patients hospitalised with COVID-
19 in the UK. The trial is underway at 177 NHS hospitals from across the UK. Eligible and …
Save Cite Cited by 334 Related articles All 22 versions